Table 1 Clinical characteristics of the population with high and low CCR5 expression group
From: CT-based machine learning radiomics predicts CCR5 expression level and survival in ovarian cancer
Variables | Total (n = 343) | High (n = 179) | Low (n = 164) | p |
|---|---|---|---|---|
Age, n (%) | ||||
 <65 | 220 (64) | 124 (69) | 96 (59) | 0.05 |
 ≥65 | 123 (36) | 55 (31) | 68 (41) |  |
Chemotherapy, n (%) | ||||
 NO | 22 (6) | 14 (8) | 8 (5) | 0.373 |
 YES | 321 (94) | 165 (92) | 156 (95) |  |
FIGO, n (%) | ||||
 I/II | 19 (6) | 10 (6) | 9 (5) | 1 |
 III/IV | 321 (94) | 167 (93) | 154 (94) |  |
 Unknown | 3 (1) | 2 (1) | 1 (1) |  |
Lymphatic invasion, n (%) | ||||
 NO | 40 (12) | 18 (10) | 22 (13) | 0.326 |
 Unknown | 210 (61) | 107 (60) | 103 (63) |  |
 YES | 93 (27) | 54 (30) | 39 (24) |  |
Neoplasm histologic grade, n (%) | ||||
 G1/G2 | 42 (12) | 21 (12) | 21 (13) | 0.67 |
 GX/Unknown | 8 (2) | 3 (2) | 5 (3) |  |
 G3/G4 | 293 (85) | 155 (87) | 138 (84) |  |
Radiotherapy, n (%) | ||||
 NO | 321 (94) | 170 (95) | 151 (92) | 0.382 |
 YES | 22 (6) | 9 (5) | 13 (8) |  |
Tumor residual disease, n (%) | ||||
 No/Unknown | 94 (27) | 45 (25) | 49 (30) | 0.389 |
 YES | 249 (73) | 134 (75) | 115 (70) |  |
Venous invasion, n (%) | ||||
 NO | 32 (9) | 14 (8) | 18 (11) | 0.571 |
 Unknown | 251 (73) | 132 (74) | 119 (73) |  |
 YES | 60 (17) | 33 (18) | 27 (16) |  |